Evidence map›Paper›PMID 29543843›Full record

ArticlePloS one2018

Type 2 diabetes is associated with loss of HDL endothelium protective functions.

Tomáš Vaisar, Erica Couzens, Arnold Hwang, Michael Russell, Carolyn E Barlow, Laura F DeFina, Andrew N Hoofnagle, Francis Kim

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. HDL metabolism and function in diabetes mellitus.Nature reviews. Endocrinology · 2026
    Review
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tomáš VaisarUW Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0002-7406-6606
Erica CouzensUW Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington, United States of America.
Arnold HwangUW Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington, United States of America.
Michael RussellUW Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington, United States of America.
Carolyn E BarlowThe Cooper Institute, Dallas, Texas, United States of America.
Laura F DeFinaThe Cooper Institute, Dallas, Texas, United States of America.
Andrew N HoofnagleDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America.
Francis KimUW Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, Washington, United States of America.
University of Washington · USCooper Institute · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
PILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI Ellen A Schur · 1986 to 2026
$30.4M
Role of Serum Amyloid A in Diabetic Vascular DiseaseP01HL092969 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E. · 2008 to 2019
$23.5M
Diabetes, Obesity and Metabolism Training ProgramT32DK007247 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON, KRISTINA Marie UTZSCHNEIDER · 1986 to 2026
$10.0M
Endothelial nitric oxide synthase and regulation of macrophage functionR01DK106703 · NIDDK · UNIVERSITY OF WASHINGTON · PI KIM, FRANCIS · 2016 to 2019
$1.8M
HDL and cardiovascular risk in chronic kidney diseaseR01HL111375 · NHLBI · UNIVERSITY OF WASHINGTON · PI HOOFNAGLE, ANDREW N · 2012 to 2015
$1.5M
NHLBI NIH HHS P01 HL092969NHLBI NIH HHS R01 HL111375NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK035816NIDDK NIH HHS R01 DK106703NIDDK NIH HHS T32 DK007247NIH HHS DK035816NIH HHS DK106703NIH HHS HL111375
6 · The paper itself

Abstract

aims/hypothesisOne of the hallmarks of diabetes is impaired endothelial function. Previous studies showed that HDL can exert protective effects on endothelium stimulating NO production and protecting from inflammation and suggested that HDL in obese people with diabetes and dyslipidemia may have lower endothelial protective function. We aimed to investigate whether type 2 diabetes impairs HDL endothelium protective functions in people with otherwise normal lipid profile.

methodsIn a case-control study (n = 41 per group) nested in the Cooper Center Longitudinal Study we tested the ability of HDL to protect endothelium by stimulating endothelial nitric oxide synthase activity and suppressing NFκB-mediated inflammatory response in endothelial cells. In parallel we measured HDL protein composition, sphinogosine-1-phosphate and P-selectin.

resultsDespite similar levels of plasma HDL-C the HDL in individuals with type 2 diabetes lost almost 40% of its ability to stimulate eNOS activity (P<0.001) and 20% of its ability to suppress TNFα-dependent NFκB-mediated inflammatory response in endothelial cells (P<0.001) compared to non-T2D controls despite similar BMI and lipid profile (HDL-C, LDL-C, TC, TG). Significantly, the ability of HDL to stimulate eNOS activity was negatively associated with plasma levels of P-selectin, an established marker of endothelial dysfunction (r = -0.32, P<0.001). Furthermore, sphingosine-1-phosphate (S1P) levels were decreased in diabetic plasma (P = 0.017) and correlated with HDL-mediated eNOS activation. CONCLUSIONS/INTERPRETATIONS: Collectively, our data suggest that HDL in individuals with type 2 diabetes loses its ability to maintain proper endothelial function independent of HDL-C, perhaps due to loss of S1P, and may contribute to development of diabetic complications.

Indexed as

AgedAnimalsCase-Control StudiesCattleCells, CulturedDiabetes Mellitus, Type 2Endothelium, VascularFemaleHumansLipoproteins, HDLLongitudinal StudiesLysophospholipidsMaleMiddle AgedNF-kappa BNitric Oxide Synthase Type IIILipoproteins, HDLLysophospholipidsNF-kappa BNitric Oxide Synthase Type IIINOS3 protein, humanP-SelectinSELP protein, humanSphingosinesphingosine 1-phosphate

Identifiers

PMID29543843
PMCPMC5854245
OpenAlexW2793079430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.